ADC Therapeutics SA (ADCT) Stock Price

ADCTStock

$1.14−64.92%52W

Market Cap$145.54M

P/E—

PEG Ratio—

Div yield—

Beta1.87

ADCT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-85.96%

Price vs S&P 500 (4W)7.03%

VGM Score47.78

Book Value / Share (Quarterly)$0.47

P/TBV (Annual)3.97x

Revenue Growth (3Y)-27.09%

Cash Flow / Share (Quarterly)$-0.90

Price vs S&P 500 (YTD)-80.53%

Gross Margin (TTM)90.71%

Net Profit Margin (TTM)-173.02%

EPS (TTM)$-1.12

10-Day Avg Trading Volume2.31M

EPS Excl Extra (TTM)$-1.12

Revenue Growth (5Y)98.48%

EPS (Annual)$-1.12

ROI (Annual)-37.24%

Gross Margin (Annual)92.87%

Net Profit Margin (5Y Avg)-299.19%

Cash / Share (Quarterly)$1.82

Revenue Growth QoQ (YoY)-9.47%

ROA (Last FY)-44.14%

Revenue Growth TTM (YoY)4.43%

EBITD / Share (TTM)$-0.89

ROE (5Y Avg)-117.97%

Operating Margin (TTM)-149.39%

Cash Flow / Share (Annual)$-1.12

P/B Ratio3.53x

P/B Ratio (Quarterly)4.17x

Net Income / Employee (Annual)$-758,600

EV / Revenue (TTM)4.07x

Net Interest Coverage (TTM)-2.26x

ROA (TTM)-44.70%

EPS Incl Extra (Annual)$-1.12

Current Ratio (Annual)4.37x

Quick Ratio (Quarterly)3.94x

3-Month Avg Trading Volume1.73M

52-Week Price Return-64.92%

Revenue / Employee (TTM)$421,100

Tangible BV / Share (Quarterly)$0.30

P/S Ratio (Annual)1.63x

Asset Turnover (Annual)0.25x

52-Week High$4.98

Operating Margin (5Y Avg)-284.41%

EPS Excl Extra (Annual)$-1.12

CapEx CAGR (5Y)-37.69%

Tangible BV CAGR (5Y)-21.14%

26-Week Price Return-74.03%

Quick Ratio (Annual)4.23x

13-Week Price Return-66.96%

Total Debt / Equity (Annual)3.72x

Current Ratio (Quarterly)4.09x

Enterprise Value$322.27M

Revenue / Share Growth (5Y)89.29%

Asset Turnover (TTM)0.26x

Book Value / Share Growth (5Y)-19.47%

Revenue / Employee (Annual)$432,800

Inventory Turnover (Annual)0.51x

Pretax Margin (Annual)-174.06%

Cash / Share (Annual)$2.08

3-Month Return Std Dev142.98%

Gross Margin (5Y Avg)95.14%

Net Income / Employee (TTM)$-728,700

ROE (Last FY)-175.65%

Net Interest Coverage (Annual)-2.32x

EPS Basic Excl Extra (Annual)$-1.12

Receivables Turnover (TTM)2.52x

Total Debt / Equity (Quarterly)9.01x

EPS Incl Extra (TTM)$-1.12

Receivables Turnover (Annual)3.29x

ROI (TTM)-48.19%

P/S Ratio (TTM)1.68x

Pretax Margin (5Y Avg)-298.20%

Revenue / Share (Annual)$0.64

Tangible BV / Share (Annual)$0.92

Price vs S&P 500 (52W)-83.48%

Year-to-Date Return-67.71%

5-Day Price Return18.12%

EPS Normalized (Annual)$-1.12

ROA (5Y Avg)-45.50%

Net Profit Margin (Annual)-175.31%

Month-to-Date Return8.57%

Cash Flow / Share (TTM)$-2.16

EBITD / Share (Annual)$-0.95

Operating Margin (Annual)-149.34%

LT Debt / Equity (Annual)3.49x

ROI (5Y Avg)-69.52%

LT Debt / Equity (Quarterly)8.32x

EPS Basic Excl Extra (TTM)$-1.12

P/TBV (Quarterly)6.53x

P/B Ratio (Annual)3.33x

Inventory Turnover (TTM)0.66x

Pretax Margin (TTM)-171.95%

Book Value / Share (Annual)$1.10

Price vs S&P 500 (13W)-68.91%

Beta1.87x

Revenue / Share (TTM)$0.51

ROE (TTM)-229.23%

52-Week Low$0.78

vGradeB

gGradeC

mGradeD

vgmGradeC

ADCT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.22	-$0.11	+49.07%(+$0.11)
Q1 2026	May 4, 2026	-$0.20	-$0.21	-4.13%(-$0.01)
Q4 2025	Mar 10, 2026	-$0.27	-$0.04	+85.09%(+$0.23)
Q3 2025	Nov 10, 2025	-$0.36	-$0.30	+17.43%(+$0.06)
Q2 2025	Aug 12, 2025	-$0.48	-$0.50	-4.89%(-$0.02)

ADCT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.33

3.83

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ADCTADC Therapeutics SA	B	C	D	$1.14
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About ADC Therapeutics SA

ADC Therapeutics is an oncology-focused biotechnology company with an FDA-approved product, ZYNLONTA, for relapsed or refractory large B-cell lymphoma. The company develops antibody-drug conjugates (ADCs) targeting hematological malignancies and solid tumors, supported by a pipeline of candidates across multiple mechanisms. Revenue is generated primarily from the United States and Europe.